Clinical Trial Update: A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports results from a Phase 1/2 study evaluating lanraplenib in combination with gilteritinib in FLT3-mutated relapsed or refractory…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Gilteritinib (gilteritinib)
• Lanraplenib (LANRA) (lanraplenib)

Snippet

Sponsor: Kronos Bio | Conditions: Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-08-07